P-49 COVID 19-PANDEMIC AND OUTCOMES IN DECOMPENSATE CIRRHOSIS-10 MONTHS REVIEW

• Main Authors: Priscila Pollo-Flores, Gabriel Alverca Meyas, Vanessa Rodrigues, Janaisa Moraes de Souza, Pamela Moura Rodrigues Cardoso, Iasmin Torres Leitão, Stephanie Cathren Fenizola dos Santos da Silva, Lívia Melo Villar
• Format: Article
• Language: English
• Published: Elsevier 2021-09-01
• Series: Annals of Hepatology
• Online Access: http://www.sciencedirect.com/science/article/pii/S1665268121001125

Background and Aims: Liver abnormalities are frequent in COVID-19 disease, AST and ALT abnormalities are present in about 60% of serious disease patients. However, liver insufficiency and liver mortality were not important concerns. Decompensate cirrhotic patients are a group of high risk for morbidity and mortality. Consequently, we aimed to study cirrhotic patients with at least one complication: ascites, encephalopathy or esophageal varices; to investigate mortality, transplantation and hospitalization due to SARS-Covid-19 infection pandemic. Methods: Liver unit patients were enrolled after ethical approval and signed consentiment term. Combined outcomes during pandemic were analyzed. Participants were submitted to SARS-Cov 2 test by PCR oro/pharingeal swab. Call phone and medical records were consulted for covid 19 symptoms and outcomes. Survival, transplantation and clinical complications were studied. Results: Fourthy seven patients were enrolled, 26 followed. Men was 73% of patients and median age was 62,7 years. The cirrhosis etiology in 35% was MAFLD, 32% alcohol, 15% HCV and 18% others. Frequence of COVID-19 infection was 42%, at last 10 months, and three (11%) patients died. Liver-related complications with death were present in 19% of patients without COVID-19 infection. Five patients (19%) were submitted to liver transplantation, without COVID-19 disease. Conclusion: Although an incipient analyzes, our data show high death rate of cirrhotic decompensate patients during COVID-19 pandemic. This population needs a specific approach in order to prevent Covid-19 infection, liver-related mortality and complications during pandemic.